Gene Therapy Weekly


Research on cancer described by scientists at University of Parma



Gene Therapy Weekly Library
Library Home

This article was published in Gene Therapy Weekly, which you can subscribe to online.
2008 JAN 17 -- According to recent research from Parma, Italy, "Besides a fully processed, secreted form of clusterin (sCLU), an alternative proapoptotic form of the protein targeting the nucleus (nCLU) was recently described."

"The possible differential roles played by the two clusterin forms in growth and motility of nonmalignant and malignant prostate cells are investigated here. sCLU or nCLU was transiently transfected in both androgen-independent prostate cancer cells (PC3 and DU 145) and immortalized prostate epithelial cells (PNT1A, a nontumoral control)," wrote R.M. Moretti and colleagues, University of Parma.

The researchers concluded: "Then, cell growth, motility, and cytoskeleton organization were studied."

Moretti and colleagues published their study in Cancer Research (Clusterin Isoforms differentially affect growth and motility of prostate cells: Possible implications in prostate tumorigenesis. Cancer Research, 2007;67(21):10325-10333).

For additional information, contact S. Bettuzzi, University of Parma, Dipartimento Med Sperimentale, Sez Biochim Biochim Clinic & Biochim Esercizio Fis, Via Volturno 39, I-43100 Parma, Italy.

Publisher contact information for the journal Cancer Research is: American Association Cancer Research, 615 Chestnut St., 17TH Floor, Philadelphia, PA 19106-4404, USA.

Keywords: Italy, Parma, Biotechnology, Cancer Research, Cell Proliferation, Gene Therapy, Genetics, Genomics, Oncology, Prostate Cancer, Prostatic Neoplasms, University of Parma.

This article was prepared by Gene Therapy Weekly editors from staff and other reports. Copyright 2008, Gene Therapy Weekly via NewsRx.com.